February 4, 2012
Pharmacy news, jobs, continuing education, community and more.
Abbott (NYSE: ABT) announced today it has received clearance from the U.S. Food and Drug Administration for a fully-automated 25-OH Vitamin D assay performed on its widely used ARCHITECT®laboratory testing platform. Published data from the Third National Health and Nutrition Survey, reported in the Archives of Internal Medicine, show that less than a quarter of [...]
Abbott (NYSE: ABT) announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. (GSK) to include the development of an additional companion diagnostic test in support of GSK’s cancer immunotherapy research program. Companion diagnostic tests are designed to identify specific DNA sequences to help guide physicians in determining which patients are more [...]
Abbott (NYSE: ABT) received approval from the U.S. Food and Drug Administration (FDA) for a new Chagas in vitro diagnostic test. The ABBOTT ESA Chagas is the first FDA-approved supplemental test that detects antibodies to Trypanosoma cruzi (T. cruzi), a parasite found only in the Americas and commonly acquired through contact with the blood-sucking triatomine, [...]
Final results were presented today from the AIM-HIGH study, a National Heart, Lung and Blood Institute (NHLBI) study. The study was designed to test whether raising HDL “good” cholesterol by adding Niaspan to simvastatin would provide an additional 25 percent reduction in cardiovascular outcomes in patients with established cardiovascular disease and well-controlled LDL “bad” cholesterol [...]
Abbott (NYSE: ABT) scientists and independent researchers will highlight the latest research findings on HUMIRA® (adalimumab) at this year’s American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago. The presentations include data on rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS) and spondyloarthritis (SpA), as well as health [...]
Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. With the introduction of XIENCE PRIME in the United States, Abbott, the worldwide leader in drug eluting stent technology, now offers physicians an [...]
Responding to the growing diabetes and obesity epidemic in the United States, Abbott (NYSE: ABT) is introducing Glucerna® Hunger Smart(TM) nutrition shakes and bars for people with diabetes. Diabetes affects more than 25 million Americans, according to the Centers for Disease Control and Prevention. If the current trend continues, one in three Americans will develop [...]
ABBOTT PARK, Ill., – Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED ® (leuprolide acetate for depot suspension) for the treatment of children with central precocious puberty (CPP). CPP is a condition that causes children to enter puberty too [...]
ATLANTA – Data presented this week at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial. According to published data from the Third National Health and Nutrition Survey, reported in the Archives of Internal Medicine, only 23 percent [...]
ATLANTA – Hospital and public health laboratories across the country are now detecting early-stage HIV infections much sooner than previous tests since the launch of Abbott’s ARCHITECT® HIV Ag/Ab Combo assay, a combination antigen-antibody test, in 2010. Researchers reported finding early stage infections in places not known for high HIV prevalence like Sioux Falls, S.D., [...]
© Rx Times, LLC 2011. All rights reserved. All products denoted with ™ and ® are trademarks or registered trademarks of Rx Times, LLC and/or its affiliates.